Letter to HFEA on Sex Selection
By Tania Simoncelli and Marcy Darnovsky
| 01. 22. 2003
Vishnee Seenundun
Consultation Co-ordinator
HFEA
Paxton House
30 Artillery Lane
London E1 7LS
Dear Vishnee Seenundun,
We are writing to express our concern regarding the HFEA's
public consultation on sex selection, and to encourage you to
ensure that strong policies are upheld and further developed
against non-medical sex selection.
The Center for Genetics and Society is a U.S.-based non-profit
public interest organization working to encourage responsible
uses and democratic governance of the new human genetic and
reproductive technologies. In our work, we look to the HFEA
as a model for responsible regulation, and consider that your
work carries critical weight for international policy making
well beyond the UK. Conversely, we feel that the HFEA would
do well to consider U.S. experience in this field, where a virtual
absence of regulation has led to a shortchanging of ethical
and social considerations and an unacceptable level of permissiveness
in the fertility industry.
In general, we are concerned by the way in which the consultation
document, "Sex selection: Choice and responsibility in
reproduction" frames the consultation process around "risks
to health" and "reliability...
Related Articles
Since the “CRISPR babies” scandal in 2018, no additional genetically modified babies are known to have been born. Now several techno-enthusiastic billionaires are setting up privately funded companies to genetically edit human embryos, with the explicit intention of creating genetically modified children.
Heritable genome editing remains prohibited by policies in the overwhelming majority of countries that have any relevant policy, and by a binding European treaty. Support for keeping it legally off limits is widespread, including among scientists...
By Ed Cara, Gizmodo | 06.22.2025
In late May, several scientific organizations, including the International Society for Cell and Gene Therapy (ISCT), banded together to call for a 10-year moratorium on using CRISPR and related technologies to pursue human heritable germline editing. The declaration also outlined...
By Isabel van Brugen, Newsweek | 06.05.2025
A U.S.-based biotech company has unveiled a new in vitro fertilization (IVF) option that allows parents to select embryos based on genetic markers tied to health and longevity.
DNA testing and analysis company Nucleus Genomics has announced the world's first...
By Jonathan D. Grinstein, PhD, Inside Precision Medicine | 06.03.2025
On Tuesday, 307 days after he was first admitted to Children’s Hospital of Philadelphia (CHOP), KJ Muldoon went home after being successfully treated with the first personalized CRISPR gene editing therapy. KJ, who was born with a serious and...
